1006 related articles for article (PubMed ID: 28942790)
21. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF; Kushner P; Aguilar R
Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
[TBL] [Abstract][Full Text] [Related]
22. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
Peng H; Want LL; Aroda VR
Curr Diab Rep; 2016 May; 16(5):44. PubMed ID: 27037706
[TBL] [Abstract][Full Text] [Related]
23. An overview of new GLP-1 receptor agonists for type 2 diabetes.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
[TBL] [Abstract][Full Text] [Related]
24. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
Lu JM
Adv Ther; 2019 Apr; 36(4):798-805. PubMed ID: 30859500
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
[TBL] [Abstract][Full Text] [Related]
26. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
27. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
28. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
29. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
Abdelmalek MF; Harrison SA; Sanyal AJ
Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
[TBL] [Abstract][Full Text] [Related]
30. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
31. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
[TBL] [Abstract][Full Text] [Related]
33. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
Busch RS; Kane MP
Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
[TBL] [Abstract][Full Text] [Related]
34. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
Seksaria S; Dutta BJ; Kaur M; Gupta GD; Bodakhe SH; Singh A
Curr Diabetes Rev; 2024; 20(6):e090823219597. PubMed ID: 37559236
[TBL] [Abstract][Full Text] [Related]
35. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
Tanaka A; Node K
Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide agonists: A prospective review.
Mariam Z; Niazi SK
Endocrinol Diabetes Metab; 2024 Jan; 7(1):e462. PubMed ID: 38093651
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
38. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
[TBL] [Abstract][Full Text] [Related]
40. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.
Lyseng-Williamson KA
Clin Drug Investig; 2019 Aug; 39(8):805-819. PubMed ID: 31317516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]